Taking stock of the drug industry, from the lab to the medicine chestJune 15, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Sebastian D'Souza/AFP/Getty Images STAT+ | USDA to push food producers to substantiate claims that animals are raised without antibiotics The USDA will push food producers to back claims that food animals are raised without antibiotics amid concerns about drug resistance. By Ed Silverman White House 'naloxone summit' omitting prominent advocates for lower costs Nonprofits say they fear companies like Narcan's manufacturer will dominate the upcoming discussion of the opioid epidemic. By Lev Facher Listen: Biogen's messy board, Laronde's data problem, & the downside of a boom STAT's Allison DeAngelis joins us to share her reporting on how the handsomely funded Laronde ran into behind-the-scenes data problems. By Damian Garde and Meg Tirrell and Adam Feuerstein Molly Ferguson/STAT STAT+ | Instead of credible data, PDS Biotech delivers 'results might get better, later' promises The company's drug, called PDS0101, is designed to recruit T cells to attack tumors caused by the human papilloma virus, or HPV. By Adam Feuerstein STAT+ | Opinion: How I'm helping companies think through whether they should cover GLP-1s like Ozempic for employees GLP-1s like Ozempic are providing not just moments of hope on scales in bathrooms but moments of reckoning in boardrooms. By Owen Tripp More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments